JNJ

Johnson & Johnson New York Stock Exchange
$163.76
Open: $162.2 High: $164.255 Low: $162.2 Close: $163.77
Range: 2021-06-19 - 2021-06-21
Volume: 2,714,050
Market: Open
Powered by Finage Stock APIDelayed data
JNJ
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick NJ, 8933 http://www.jnj.com
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
  • CEO: Alex Gorsky
  • Employees: 134,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
JNJ News
Latest news about the JNJ
  • Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients

    The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.

    View More →
  • S.Africa's Ramaphosa accuses Big Pharma of 'selfish, unjust' vaccine policy

    South Africa's president said on Monday the "selfish, unjust" refusal of pharmaceutical companies and allied Western governments to entertain emergency patent waivers on COVID-19 vaccines was endangering the entire world. In unusually impassioned remarks, Cyril Ramaphosa lambasted a resistance to calls by India and South Africa for temporary patent waivers to ramp up production. "It is selfish, it is unjust, it is wholly unfair," Ramaphosa, proponent of the waiver, told the opening virtual session of the Qatar Economic Forum, a day after South Africa registered 13,000 new cases in a third COVID-19 wave.

    View More →
  • AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

    A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.

    View More →
  • Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?

    The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.

    View More →
  • Nike, FedEx, Johnson & Johnson, Darden, and Other Stocks for Investors to Watch This Week

    Companies speaking with investors this week include Nike, FedEx, Johnson & Johnson, GlaxoSmithKline, and Darden Restaurants. Plus, PMIs, durable goods orders, and personal income and consumption.

    View More →
  • This Is Warren Buffett's Best Dividend Stock by Far

    It might seem that Warren Buffett doesn't like dividends. After all, Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has never paid a dividend. There are more stocks in Berkshire's portfolio that pay dividends than ones that don't.

    View More →
  • German lab, J&J still hashing out details of COVID-19 vaccine clot collaboration

    A scientist investigating rare blood clots possibly linked to AstraZeneca's and Johnson & Johnson's COVID-19 vaccines has yet to start a planned collaboration with the U.S. company, he said, as talks over their research pact continue. Dr. Andreas Greinacher, a transfusion medicine expert at Germany's Greifswald University, has been studying clotting with low blood platelets in people who got AstraZeneca's vaccine. In April, when clotting developed in a few people who got J&J's shot, Greinacher announced his lab would work with the U.S. company to explore causes.

    View More →
  • Is JNJ Stock A Buy As Covid Vaccinations Resume Post Blood-Clot Scare?

    Is JNJ stock a buy after U.S. regulators recommended vaccinations resume with Johnson & Johnson's Covid vaccine following worries of blood clots? Shares are forming a flat base.

    View More →
  • The latest on the Covid-19 pandemic in the U.S.

    Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joined Yahoo Finance to discuss the latest on covid.

    View More →
  • 10 Best Healthcare Stocks to Buy According to Hedge Funds

    In this article, we will take a look at some of the best healthcare stocks to buy based on the data of over 860 hedge funds tracked by Insider Monkey. You can skip our detailed analysis of the healthcare industry and go directly to see 5 Best Healthcare Stocks to Buy According to Hedge Funds. […]

    View More →
  • Affordable Care Act survives third Supreme Court challenge

    Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.

    View More →
  • Mayo Clinic, nference AI Analysis Find No Real-World Link Between COVID-19 Shots And Clots

    A new study from the artificial intelligence (AI)-driven health technology company, nference, and the Mayo Clinic, finds no links among any of the three COVID-19 vaccines and cerebral venous sinus thrombosis, the rare brain clots known as CVST. What Happened: Inoculations from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), and Johnson & Johnson (NYSE: JNJ) were included in the study. The study results were published this week in the Journal of Stroke and Cerebro

    View More →
  • Supreme Court upholds Obamacare in latest ruling

    On Thursday, the Supreme Court released its highly anticipated decision on a challenge to the Affordable Care Act (ACA), also known as Obamacare. By a 7-2 vote, the court rejected the Republican-led challenge to the law.

    View More →
  • EU drug regulator records 415 cases of possible rare blood clotting

    The EU drug regulator said on Thursday it has received reports of 415 possible cases of rare blood clotting with a low platelet count in the European Economic Area, out of more than 50 million people who have received AstraZeneca and Johnson & Johnson COVID-19 vaccines. There have been 10 possible cases among just under 6 million people who received J&J's shot in the EEA, and 405 cases among 45 million who received AstraZeneca's shot, Georgy Genov, head of pharmacovigilance at the European Medicines Agency said in a briefing. The condition is known as thrombosis with thrombocytopenia syndrome (TTS).

    View More →
  • Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

    View More →
  • By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.

    View More →
  • Here's Why Orphazyme Shares Rocketed Higher on Wednesday

    A sign there could be a buyout offer on the table sent this volatile biotech stock through the roof today.

    View More →
  • COVID-19 pandemic is ‘far from over in other parts of the world’: Doctor

    Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

    View More →
  • JNJ Unlikely To Meet Q2 COVID-19 Vaccine Supply Target To EU: Reuters

    Johnson & Johnson (NYSE: JNJ) will miss its COVID-19 vaccine supply target to the European Union for the second quarter after millions of doses were found unfit for use, Reuters reported citing the E.U. Commission spokesman. The EMA last week said JNJ doses sent to Europe from a factory in the U.S. would not be used as a precaution after a case of contamination. In a statement to Reuters, EMA said that 17 million doses had been forbidden from being used in the bloc. “Following the non-release of

    View More →
  • FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

    View More →